Literature DB >> 16459340

Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.

S I R Noble1, A Nelson, C Turner, I G Finlay.   

Abstract

OBJECTIVE: To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromoprophylaxis on overall quality of life.
DESIGN: Qualitative study using audiotaping of semistructured interviews.
SETTING: Regional cancer centre in Wales. PARTICIPANTS: 28 inpatients with advanced metastatic cancer receiving palliative care and low molecular weight heparin. MAIN OUTCOME MEASURES: Recurring themes on the effect of thromboprophylaxis on overall quality of life.
RESULTS: Major emerging themes showed that patients knew about the risks of venous thromboembolism and the purpose of treatment with heparin. Media coverage had raised awareness about venous thromboembolism, and many had previous experience of thromboprophylaxis. All found low molecular weight heparin an acceptable intervention, and many said that it improved their quality of life by giving them a feeling of safety and reassurance. Antiembolic stockings were considered uncomfortable and had a negative impact on quality of life. Patients were concerned that because they had advanced disease they might not be eligible for thromboprophylaxis.
CONCLUSION: Low molecular weight heparin is acceptable to inpatients with advanced cancer receiving palliative care and has a positive impact on overall quality of life. Antiembolic stockings are an unacceptable intervention in this patient group. Guidelines on thromboprophylaxis are urgently needed for palliative care inpatient units and hospices.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16459340      PMCID: PMC1397778          DOI: 10.1136/bmj.38733.616065.802

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  9 in total

1.  Have palliative care teams' attitudes toward venous thromboembolism changed? A survey of thromboprophylaxis practice across British specialist palliative care units in the years 2000 and 2005.

Authors:  Simon I R Noble; Ilora G Finlay
Journal:  J Pain Symptom Manage       Date:  2006-07       Impact factor: 3.612

2.  Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study.

Authors:  Simon I R Noble; I G Finlay
Journal:  Palliat Med       Date:  2005-04       Impact factor: 4.762

Review 3.  Rigour and qualitative research.

Authors:  N Mays; C Pope
Journal:  BMJ       Date:  1995-07-08

4.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

5.  The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer.

Authors:  M J Johnson; M W Sproule; J Paul
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

Review 6.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?

Authors:  V S Shen; E W Pollak
Journal:  South Med J       Date:  1980-07       Impact factor: 0.954

8.  Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management.

Authors:  R L Bick
Journal:  Semin Thromb Hemost       Date:  1978       Impact factor: 4.180

9.  Causes of death in cancer patients.

Authors:  J L Ambrus; C M Ambrus; I B Mink; J W Pickren
Journal:  J Med       Date:  1975
  9 in total
  18 in total

1.  Prophylactic heparin in palliative care: a cautious welcome...

Authors:  Victor Pace; Emma Hall; Catherine Bailey
Journal:  BMJ       Date:  2006-03-25

2.  Prophylactic heparin in palliative care: ...to a challenging idea.

Authors:  John C Chambers
Journal:  BMJ       Date:  2006-03-25

Review 3.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Samantha MacLean; Sohail Mulla; Elie A Akl; Milosz Jankowski; Per Olav Vandvik; Shanil Ebrahim; Shelley McLeod; Neera Bhatnagar; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Predictors of anticoagulation in hospice patients with lung cancer.

Authors:  Holly M Holmes; Kevin T Bain; Ali Zalpour; Ruili Luo; Eduardo Bruera; James S Goodwin
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

5.  Thromboprophylaxis in patients receiving inpatient palliative care: a survey of present practice in Austria.

Authors:  Verena Gartner; Katharina A Kierner; Astrid Namjesky; Birgit Kum-Taucher; Bernhard Hammerl-Ferrari; Herbert H Watzke; Cornelia Stabel
Journal:  Support Care Cancer       Date:  2011-11-26       Impact factor: 3.603

6.  Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer.

Authors:  Thomas Delate; Daniel M Witt; Debra Ritzwoller; Jane C Weeks; Lawrence Kushi; Mark C Hornbrook; Erin J Aiello Bowles; Deborah Schrag
Journal:  Oncologist       Date:  2012-02-14

Review 7.  Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?

Authors:  Philippe Debourdeau; Ismail Elalamy; Axelle de Raignac; Paul Meria; Jean Marc Gornet; Yahovi Amah; Wolfang Korte; Michel Marty; Dominique Farge
Journal:  Support Care Cancer       Date:  2008-08-15       Impact factor: 3.603

8.  Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines.

Authors:  Itziar Etxeandia-Ikobaltzeta; Yuan Zhang; Francesca Brundisini; Ivan D Florez; Wojtek Wiercioch; Robby Nieuwlaat; Housne Begum; Carlos A Cuello; Yetiani Roldan; Ru Chen; Chengyi Ding; Rebecca L Morgan; John J Riva; Yuqing Zhang; Rana Charide; Arnav Agarwal; Sara Balduzzi; Gian Paolo Morgano; Juan José Yepes-Nuñez; Yasir Rehman; Ignacio Neumann; Nicole Schwab; Tejan Baldeh; Cody Braun; María Francisca Rodríguez; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-03-10

Review 9.  Cancer and thrombosis: an increasingly important association.

Authors:  Wolfgang Korte
Journal:  Support Care Cancer       Date:  2008-01-16       Impact factor: 3.603

Review 10.  Decision making about change of medication for comorbid disease at the end of life: an integrative review.

Authors:  Ronald T C M van Nordennen; Jan C M Lavrijsen; Kris C P Vissers; Raymond T C M Koopmans
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.